ABIVAX Société Anonyme (ABVX) fair value analysis
Nasdaq · Updated 2026-10-19
ABVX price how computed
Valuation status
Reports in EURABVX reports its results in EUR while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for ABVX until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in EUR.
- Last price
- $95.10
- Sector
- Healthcare
- 12-month range
- $72.50–$145.31
- Market cap
- $8.3B
- From 52-week high
- -34.6%
- Shares outstanding
- 87.3M
- Rank in Healthcare by quality score
- #215 of 301
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-16.
ABIVAX Société Anonyme is a clinical-stage biopharmaceutical company focused on developing therapeutic vaccines and immunotherapies for infectious diseases and oncology. The company is based in France and operates in the biotechnology and pharmaceutical development sector.
ABVX currently ranks #215 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in EUR; the trailing P/E is omitted because an EPS in EUR against a US-dollar share price would mislead.
- Market cap
- $8.3B
- Revenue (TTM)
- -EUR 2.02M
- Net margin
- 30091.6%
- EPS (TTM)
- EUR -6.07
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- -33.3%
- Shares outstanding
- 87.3M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 34 · neutral
- 50-day average
- $106.91
- 200-day average
- $115.80
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▼ miss (-58.3%)
2026-03 ▲ beat (+12.3%)
2025-12 ▼ miss (-13.5%)
2025-09 ▼ miss (-212.7%)
2025-06 ▲ beat (+6.3%)
2025-03 ▼ miss (-25.0%)
2024-12 ▲ beat (+36.9%)
2024-09 ▲ beat (+8.9%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 12 buy · 0 hold · 0 sell (12 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $164
- Target vs last price
- +72.5%
What our data shows for ABVX
- Shares are trading in the lower third of their 12-month price range of $72.50–$145.31.
- The 14-day relative strength index sits at a neutral 34.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ABVX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ABVX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — ABVX moved out of oversold territory this week as its Relative Strength Index shifted to neutral zone. The healthcare stock's technical positioning has improved from its previous oversold state. TickrTrends' valuation assessment remains incomplete pending additional analysis.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for ABVX show several shifts this week. The balance-sheet leverage band moved from none to low, the 50/200-day trend state declined from mixed to downtrend, the revenue growth band transitioned from none to declining, and the RSI zone shifted from neutral to oversold. The current valuation verdict remains awaiting full valuation.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ABVX stock undervalued?
ABVX reports its results in EUR while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for ABVX until same-currency inputs are available.
What is ABVX's TickrTrends verdict?
ABVX is currently marked 'Reports in EUR' - no verdict is published on inputs in two different currencies.
How does ABVX compare to other Healthcare stocks?
ABVX ranks #215 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ABVX overbought or oversold?
ABVX's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does ABVX usually beat earnings estimates?
Over its last 8 reported quarters ABVX beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ABVX?
Of 12 analysts covering ABVX, 12 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $164 (+72.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.